- Discovery work on Clostridium difficile toxin inhibitors published
- Inositec’s INS-3001 Significantly Reduces Vascular Calcification Data Presented at Kidney Week 2018 Indicates
- Inositec AG Appoints Dr Frits van Alphen as Chief Medical Officer
- Inositec wins Swiss Technology Award 2017
- Inositec featured in BioCentury
Author Archives: ino_admin
The early work on the rational design of Clostridium difficile toxin inhibitors based on inositol hexaphosphate analogs has been published in Cell Chemical Biology. Our Clostridium difficile inhibitors are available for partnering and we are happy to discuss further details with interested parties. Please … Continue reading
Inositec’s INS-3001 Significantly Reduces Vascular Calcification Data Presented at Kidney Week 2018 Indicates
Zurich, Switzerland, 26 October 2018 – Inositec, a pioneer in the development of life-saving small molecule drugs based on myo-inositol hexaphosphate (IP6), announced today that INS-3001, a novel vascular calcification inhibitor, demonstrated the ability to significantly inhibit the calcification process … Continue reading
Zurich, Switzerland, 18 January 2018 – Inositec, a pioneer in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), announced today the appointment of Frits van Alphen, MD, as Chief Medical Officer. Dr van Alphen has over … Continue reading
We are proud to have won the Swiss Technology Award 2017. More information here (German).
BioCentury is featuring Inositec in this week’s emerging company profile. Read the article here (requires subscription).
Scrip Intelligence interviewed Mattias Ivarsson at BIO Europe 2016 in Cologne. The video can be found here.
Inositec AG Secures CHF1.4 million in Seed Financing to Advance New Class of Inositol Hexaphosphate-Based Drug Candidates
Lead programs address unmet medical needs in vascular calcification and C. difficile infection Zurich, Switzerland, 27th October 2016 – Inositec, a pioneer in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), announced today the closing of a … Continue reading
Inositec has been short-listed together with 10 nominees for the deVigier prize. More info here. 29th March 2016
Mattias Ivarsson appeared in the Science and Healthcare category of the 2016 Forbes 30 under 30 European list. 1st March 2016